# A. John Iafrate

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/a-john-iafrate/

## Facts

| Field | Value |
| --- | --- |
| Citations | 80,062 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 129 |
| i10-index | 322 |
| Last Known Institution | Massachusetts General Hospital |
| OpenAlex ID | https://openalex.org/A5056275493 |
| ORCID iD | 0000-0002-7888-4067 |
| Works | 879 |

## Researcher papers

Showing 12 of 28.

- [Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer](https://scholariq.org/papers/anaplastic-lymphoma-kinase-inhibition-in-non-small-cell-lung-cancer/)
- [Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors](https://scholariq.org/papers/genotypic-and-histological-evolution-of-lung-cancers-acquiring-resistance-to/)
- [Detection of large-scale variation in the human genome](https://scholariq.org/papers/detection-of-large-scale-variation-in-the-human-genome/)
- [GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases](https://scholariq.org/papers/guide-seq-enables-genome-wide-profiling-of-off-target-cleavage-by-crispr-cas/)
- [Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer](https://scholariq.org/papers/crizotinib-in-i-ros1-i-rearranged-non-small-cell-lung-cancer/)
- [Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor <i>EML4-ALK</i>](https://scholariq.org/papers/clinical-features-and-outcome-of-patients-with-non-small-cell-lung-cancer-who/)
- [Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs](https://scholariq.org/papers/using-multiplexed-assays-of-oncogenic-drivers-in-lung-cancers-to-select-targeted/)
- [Detection of Mutations in <i>EGFR</i> in Circulating Lung-Cancer Cells](https://scholariq.org/papers/detection-of-mutations-in-i-egfr-i-in-circulating-lung-cancer-cells/)
- [<i>ROS1</i> Rearrangements Define a Unique Molecular Class of Lung Cancers](https://scholariq.org/papers/i-ros1-i-rearrangements-define-a-unique-molecular-class-of-lung-cancers/)
- [Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity](https://scholariq.org/papers/multiple-sars-cov-2-variants-escape-neutralization-by-vaccine-induced-humoral/)
- [Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers](https://scholariq.org/papers/mechanisms-of-acquired-crizotinib-resistance-in-alk-rearranged-lung-cancers/)
- [Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study](https://scholariq.org/papers/activity-and-safety-of-crizotinib-in-patients-with-alk-positive-non-small-cell/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Glioma Diagnosis and Treatment](https://scholariq.org/topics/glioma-diagnosis-and-treatment/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)

## Researcher university

- [Massachusetts General Hospital](https://scholariq.org/institutions/massachusetts-general-hospital/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.